Demographic, clinical and MRI data of MOG-Ab positive patients
| Number of cases analysed | 38 |
| Age at sampling, median (range), years | 35.5 (6–75) |
| Female, n (%) | 16 (42.1) |
| Paediatric cases, n (%) | 3 (7.9) |
| Symptoms at sampling, n (%) | |
| ON | 20 (52.6) |
| Myelitis | 10 (26.3) |
| ON+myelitis | 2 (5.3) |
| Encephalopathy | 3 (7.9) |
| Encephalomyelitis | 1 (2.6) |
| None | 2 (5.3) |
| Attack at sampling | |
| Severe, n (%) | 14 (36.8) |
| EDSS, median (range) | 2.75 (0–8.5) |
| Treatment at sampling, n (%) | |
| Steroids | 5 (13.2) |
| Mycophenolate mofetil | 1 (2.6) |
| Steroids and methotrexate | 1 (2.6) |
| None | 31 (81.6) |
| Optic neuritis (ever), n (%) | 27 (71) |
| Myelitis (ever), n (%) | 17 (44.7) |
| Course, n (%) | |
| Monophasic | 20 (52.6) |
| Relapsing | 18 (47.4) |
| Radiological activity at sample, n (%) | 23 (60.5) |
| Disease duration, median (range), months | 1.5 (0–264) |
| Final diagnosis, n (%) | |
| ON/CRION | 14 (36.8) |
| Myelitis | 4 (10.5) |
| NMOSD | 4 (10.5) |
| MS | 2 (5.3) |
| ADEM | 2 (5.3) |
| Idiopathic demyelinating disorder | 12 (31.6) |
| Follow-up, median (range), months | 19.5 (2–266) |
| Final outcome, n (%) | |
| No improvement | 8 (21) |
| Partial recovery | 18 (47.4) |
| Complete recovery | 12 (31.6) |
| EDSS at last evaluation, median (range) | 1 (0–7.5) |
| Brain MRI at sampling | |
| T2 inflammatory lesions, n (%) | |
| None | 21 (55.3) |
| 1–2 | 8 (21) |
| >2 | 9 (23.7) |
| Optic nerve involvement, n (%) | |
| None | 27 (71) |
| Unilateral | 5 (13.2) |
| Bilateral | 6 (15.8) |
| Enhancing lesions, n (%) | 6 (15.8) |
| Spinal cord MRI at sampling | |
| Number of cases analysed | 34 |
| T2 inflammatory lesions, n (%) | |
| None | 21 (61.8) |
| 1–2 | 4 (11.7) |
| >2 | 9 (26.5) |
| LETM at sampling, n (%) | 3 (8.8) |
| Enhancing lesions n, (%) | 5 (14.7) |
| Laboratory data | |
| MOG-Ab titre, median (range) | 1:640 (1:160-1:81920) |
| NfL serum pg/mL, median (range) | 10.7 (2.1–101.5) |
| NfL CSF pg/mL (n=9), median (range) | 357.8 (165.7–2281) |
ADEM, acute disseminated encephalomyelitis; CRION, chronic relapsing inflammatory optic neuropathy; CSF, cerebrospinal fluid; EDSS, Expanded Disability Status Scale; LETM, longitudinally extensive transverse myelitis; MOG-Ab, anti-myelin oligodendrocyte glycoprotein antibodies; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorders; NfL, neurofilament light chain; ON, optic neuritis.